Nature Medicine reported that persistent CAR T cells can drive severe gut complications in multiple myeloma, shifting attention from general cytokine-related toxicities to longer-lived gastrointestinal on-target or off-target immunobiology. The work describes a mechanism in which CAR T cells continue accumulating in the digestive tract, correlating with clinically significant complications after treatment. While CAR T regimens are already associated with predictable acute adverse events, the findings emphasize the need to anticipate and manage delayed or prolonged tissue trafficking. The result matters for next-generation CAR designs and trial monitoring plans, where persistence metrics may become relevant safety endpoints alongside efficacy.
Get the Daily Brief